Fullerton Neurology and Headache Center | Fullerton, CA

Research site

(Unclaimed)

Location

100 LAGUNA RD, FULLERTON, California, United States of America

Site insights

Top conditions

Top treatments

Ocrelizumab

Gantenerumab

Galcanezumab

Fenebrutinib

KarXT

AR1001

EHP-101

Cladribine

LY3303560

Semagludtide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 19 total trials

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting

Early Alzheimer's Disease

Drug: Placebo (semaglutide)

Drug: Semagludtide

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Scleros...

Active, not recruiting

Multiple Sclerosis, Primary Progressive

Drug: Placebo matched to ocrelizumab

Drug: Placebo matched to fenebrutinib

Status recently updated

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Not yet enrolling

Enrolling

Alzheimer's Disease

Other: Placebo

Drug: KarXT

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) (FENopta)

This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokine...

Active, not recruiting

Relapsing Multiple Sclerosis

Drug: Placebo

Drug: Fenebrutinib

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: AR1001